Alecensa Receives FDA Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC
News
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Genentech’s anaplastic lymphoma kinase (ALK) inhibitor Alecensa (alectinib) for the treatment of adults with ALK-positive non-small cell lung ... Read more